Amanta Healthcare Shares Surge on Stock Exchange Debut with 7% Premium
Share this article:
Amanta Healthcare shares made a strong debut on the stock exchanges on Tuesday, listing at a premium of over 7 percent on the NSE and more than 6 percent on the BSE, in line with grey market expectations.
On the NSE, the stock opened at ₹135 per share, a 7.14% premium over the issue price of ₹126. On the BSE, it debuted at ₹134 per share, up 6.35%. The IPO, valued at ₹126 crore, was subscribed 82.60 times during the subscription period from September 1–3, 2025. Post-listing, the company’s market capitalization stood at ₹520.31 crore.
"At the upper price band, the company is valued at FY25 P/E of 46.6x, with a post-issue market capitalization of ₹4,892 million. Investors may consider booking partial profits on listing while holding the remaining shares for long-term gains," Solanki advised.
He added that Amanta Healthcare’s growth prospects lie in expanding customer relationships, new product launches, and scaling up manufacturing capacity.
With a focus on formulation expertise and advanced technology, the company aims to strengthen its presence in the domestic and global markets.
On the NSE, the stock opened at ₹135 per share, a 7.14% premium over the issue price of ₹126. On the BSE, it debuted at ₹134 per share, up 6.35%. The IPO, valued at ₹126 crore, was subscribed 82.60 times during the subscription period from September 1–3, 2025. Post-listing, the company’s market capitalization stood at ₹520.31 crore.
Expert Take on Post-Listing Strategy
According to Narendra Solanki, Head Fundamental Research, Anand Rathi Shares and Stock Brokers, the premium listing was broadly on expected lines."At the upper price band, the company is valued at FY25 P/E of 46.6x, with a post-issue market capitalization of ₹4,892 million. Investors may consider booking partial profits on listing while holding the remaining shares for long-term gains," Solanki advised.
He added that Amanta Healthcare’s growth prospects lie in expanding customer relationships, new product launches, and scaling up manufacturing capacity.
Business Profile of Amanta Healthcare
The pharmaceutical company specializes in the development, manufacturing, and marketing of sterile liquid products and select medical devices. Its portfolio includes Large Volume Parenterals (LVPs) and Small Volume Parenterals (SVPs), produced using Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM) technologies.With a focus on formulation expertise and advanced technology, the company aims to strengthen its presence in the domestic and global markets.
Investor Outlook
- Short-term investors: May book partial profits given the strong premium.
- Long-term investors: Can hold, considering the company’s robust pipeline, advanced technology platforms, and sector growth potential.
- Market watchers: Note that the listing is aligned with the strong grey market premium seen before debut.
Next Story